Dyne Therapeutics, Inc. (DYN)
$16.64+1.65%Close
SELLRECOVERY · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.8B
- Beta
- 1.12
- P/E (TTM)
- -4.62
- Short % float
- 19.28%
- Days to cover
- 9.0
- SI change
- +11.1%
- 1W
- +9.47%
- 1M
- -9.66%
- vs SPY 1W
- +8.31%
- vs SPY 1M
- -12.66%
Industry peers
FMP comparable companies · ranked by market cap
- APGEBUYApogee Therapeutics, Inc.$8.4BBULLQ 60$135.07-0.01%
- CNTACentessa Pharmaceuticals plc$6.3B$40.50
- CGONSELLCG Oncology Inc.$6.1BCRISISQ 25$68.71+0.89%
- MIRMSELLMirum Pharmaceuticals, Inc.$5.0BRECOVERYQ 37$81.43+5.73%
- TLXSELLTelix Pharmaceuticals Limited$3.7BBEARQ -4$10.88+1.82%
- XENESELLXenon Pharmaceuticals Inc.$3.6BCRISISQ 22$37.57+0.77%
- CELCSELLCelcuity Inc.$3.6BCRISISQ 27$73.62+0.10%
- SLNOSoleno Therapeutics, Inc.$2.8B$53.01
- RAREBUYUltragenyx Pharmaceutical Inc.$1.4BRECOVERYQ -6$14.50+1.24%
- AAPGSELLAscentage Pharma Group International$1.4BCRISISQ 4$14.61+1.37%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on DYN?
- LOPJLB’s latest quantitative signal on Dyne Therapeutics, Inc. (DYN) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is DYN in?
- Dyne Therapeutics, Inc. (DYN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Dyne Therapeutics, Inc. (DYN) do?
- Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystroph…